Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

Economic Burden of Adverse Events Associated With Follow-Up Frequency Among Patients With Metastatic Melanoma

This study is a real-world retrospective claims analysis to assess and compare AE-related HCRU and medical costs among patients with different follow-up frequency after initiating a melanoma therapy.

Inclusion Criteria:

• Diagnosed with metastatic melanoma
• Initiated at least 1 treatment for metastatic melanoma after 2011
• Continuous enrollment in their healthcare plan for at least 6 months before and at least 6 weeks after the index date
• Patients who received at least 1 dose of study drug in CA209-067